Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: RGNX), Kyndryl Holdings, Inc. (NYSE: KD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

accessnewswire.com
RGNX Investigation announced into allegations of materially false and misleading statements regarding RGX-111's development, clinical trial success, and efficacy/safety profile. This suggests significant concerns about the company's disclosures and product prospects. KD Investigation announced into allegations of materially misstated financial statements, inadequate internal controls, and failure to timely file a quarterly report. These are serious accounting and disclosure issues. INO Investigation announced into allegations of deficient manufacturing for the CELLECTRA device, unlikely submission of BLA, insufficient data for accelerated approval, and overstated regulatory/commercial prospects for INO-3107. RARE Investigation announced into allegations of creating a false impression about reliable information on setrusumab's effects and minimizing risks in the Phase III Orbit study, with optimism about results being misplaced.

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Lifshitz Law Firm

REGENXBIO Inc. (NASDAQ:RGNX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) REGENXBIO's representations concerning its plan to develop and commercialize RGX‑111, a one‑time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, were materially misleading; (ii) the Company's positive statements regarding the anticipated success of RGX‑111's Phase I/II clinical trial, purportedly supported by continuing favorable biomarker and safety data, lacked a reasonable basis; and (iii) the efficacy and safety profile of RGX‑111 was materially overstated.

If you are an RGNX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Kyndryl Holdings, Inc. (NYSE:KD)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) Kyndryl's financial statements issued during the Relevant Period were materially misstated; (ii) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (iii) as a result of the foregoing, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.

If you are a KD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) as a result of the foregoing, INO-3107's overall regulatory and commercial prospects were overstated.

If you are an INO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta, while also minimizing risk that patients in Ultragenyx's Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx's optimism in the Phase III Orbit study's results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.

If you are an RARE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC

Phone: 516-493-9780

Facsimile: 516-280-7376

Email:[email protected]

SOURCE: Lifshitz Law Firm